AbbVie EBITDA 2012-2026 | ABBV

AbbVie EBITDA for the quarter ending March 31, 2026 was $4.814B, a 18.54% decline year-over-year.

  • AbbVie 2024 EBITDA was 17.523B, a 18.33% decline from 2023.
  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

AbbVie EBITDA 2012-2026 | ABBV

  • AbbVie 2024 EBITDA was 17.523B, a 18.33% decline from 2023.
  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B